Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (October 2016)
25 slides from Inspiremd's investor presentation, Oct 20, 2016
Slide 1: Corporate Presentation
inspireMD Corporate Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements inspireMD This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forw
Slide 3: Investment Highlights
Investment Highlights inspireMD + Revenue growth driven by broader EU and Latin American launch of CGuard™ * Strategic distribution partnership with Penumbra (NYSE: PEN) + Multiple and consistent clinical trial results using CGuard in a broad patient population, including high risk patients « Expand
Slide 4: Embolization Can Lead to Catastrophic Health Events
Embolization Can Lead to Catastrophic 7 Ne Health Events inspireMD E WALL STREET JOURNAL. = vs. Stents Boost Stroke Recovery, Study Finds paineaciiaiaes Times Essentials Keech, ss2ren Haat se Insioe Meaty Precious Hours, Then Lives, Lost in Strokes Wake
Slide 5: Embolization Following Carotid Artery Stenting
Embolization Following Carotid Artery Stenting inspireMD “Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents in relation to plaque morphology/symptomatic status and stent type, providing a mechanism for post carotid artery stenting (CAS) cerebral embolization,
Slide 6: Consequences Range from Neurological Deficit to Stroke
Consequences Range from Neurological Deficit to Stroke Pre-Procedure Post-Procedure Pre-intervention showing 90% occlusion of the Post-intervention showing successful opening carotid artery and an MRI showing an old white of the occluded carotid artery with conventional matter infarction (obstructio
Slide 7: MicroNet Prevents Distal Embolization and Other Vascular Disease Challenges
MicroNet Prevents Distal Embolization and Other WE Vascular Disease Challenges Inspire * Proprietary technology * Ultrathin PET* mesh provides meaningful clinical benefit versus conventional devices + Provides revascularization benefit + MicroNet acts as “safety net” by offering greater vessel area
Slide 8: Large Addressable Market
Large Addressable Market Embolic Prevention Products Market Opportunity inspireMD MGuard™* CGuard™ NGuard™ PVGuard™ * MQuard ie a bare metal stent scald $1.7B $500M $675M $1.7B v v (FDA IDE draft protocol synopsis) 2017E Planned Submission 2018E Planned Submission Coronary AMI & SVG Carotid Neurovas
Slide 9: Carotid Solution: Mesh Covered Technology
Carotid Solution: Mesh Covered Technology inspireMD CGuard Embolic Prevention System(EPS) Combines stent and embolic protection in a single system + CE marked + Selftexpanding nitinol stent + Emerging global market opportunity valued at $500M* * Positive CARENET data released 9/14, 1/15 and 5/16 doc
Slide 10: Positive CGuard Clinical Experience
Positive CGuard Clinical Experience inspireMD CARENET Clinical Trial: 30 patient safety and efficacy clinical trial Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%") 50% fewer new ischemic lesions with lesion volume being 10x times smaller compared to histori
Slide 11: Additional Independent Clinical Data Supports Use of CGuard
Additional Independent Clinical Data Supports 7 Ne Use of CGuard* inspireMD Independent study conducted in 30 patients with internal carotid artery disease ono CClinial Results and Mechanical Properties fof the Carotid CGUARD Double-Layered Embotie Prevention Stent Ee Clinical results * 100% success
Slide 12: Data Presented at CIRSE 2016
Data Presented at CIRSE 2016 inspireMD Laboratory engineering evaluations + CGuard EPS provides high radial force and strong support in long stenotic lesions Wall adaption in comparison to Competitor + Structure adapted well to changes in vessel diameter and direction + MicroNet mesh of CGuard EPS d
Slide 13: CGuard is a “Game Changing” Carotid Solution
CGuard is a “Game Changing” Carotid Ns Market Opportunity inspireMD Current standard of care: Carotid Endarterectomy (CEA) = Surgery The risk of post-procedural cerebral events has been related to [conventional] carotid stents* + Higher risks of stroke at 10 years appear to be attributable to the pe
Slide 14: Broad EU Commercialization Support from a Growing Neurovascular Leader
Broad EU Commercialization Support from a aie Growing Neurovascular Leader Inspir eMD Penumbra rp) * Strategic distribution agreement with Penumbra * 18 European markets with opportunity to expand + Comprehensive neurovascular product portfolio * CGuard is a synergistic product offering + Growing di
Slide 15: CGuard Country Case Study - Italy
CGuard Country Case Study - Italy inspireMD 194% sales growth in Q2 2016, compared to Q2 2015 20% growth compared to the Q1 2016 Italy CGuard Revenue (in 00's) $137 all qiis Q116 * Setacci at. al, J Cardiovasc Surg. 2015 May 21 15
Slide 16: Expanding Pipeline Opportunities with MicroNet
Expanding Pipeline Opportunities with MicroNet inspireMD Commercial + CE Mark Cleared + 12-month MASTER |, Il MGuard™ Corona . EPS ” Commercial CE Mark Cleared Exploring Market RGuard™ CGuard™ CARENET Trial portunity i Renal" Carotid PARADIGM all-comer trials Wissgott 2016 data E FDA IDE draft proto
Slide 17: Flow Diversion for Neurovascular Aneurysms
Flow Diversion for Neurovascular Aneurysms inspireMD Objective * Seal the aneurysm and prevent rupture Current device therapies * Coils to pack the aneurysm + Flow diverters + Highly flexible, dense metal “tube” + Placed in main artery to seal off aneurysm and cause aneurysm thrombosis + Precise del
Slide 18: MicroNet Enables Growth in the Neurovascular Market
fe etlas Enables Growth in the Neurovascular inspir eMD Flow Diversion for Unruptured Brain Aneurysms Next Generation Technology + Aneurysm Therapy (all types): $550M* + Flow diverters are estimated to be 25% of the aneurysm market « Neurovascular products: estimated 15% CAGR from 2010-2016 Global F
Slide 19: InspireMD Flow Diverter Advantage
InspireMD Flow Diverter Advantage inspireMD + Low profile, flexible, open cell scaffold = Easy to deliver * Low metal ratio = Potential for reduced anti-thrombosis medication + Re-accessible through MicroNet = Allows for further treatment, if needed which is impossible with current flow diverters *
Slide 20: Intellectual Property Portfolio
Intellectual Property Portfolio inspireMD * Proprietary platform technology supported by a robust intellectual property portfolio. * Continue to strengthen and broaden patent protection globally. + Progress over the last year imparts important rights on existing products and technologies and will en
Slide 21: Upcoming Anticipated Milestones
Upcoming Anticipated Milestones inspireMD development towards PVGuard rk Planned Submission India Guard: 2017 U.S. IDE submission 2016 2017 2018 2
Slide 22: Leadership
Leadership Significant track records of success inspireMD Dr. James Barry President and CEO gBostony (Pfizer Craig Shore CFO (Pfizer) @ 4 VP Global Marketing & Boston, David Blossom Strategy Seientific EI COVIDIEN Dr. Sol Barer Chairman Isaac Blech Vice Chairman R= ® Sperecor G medgenies Rise Michae
Slide 23: Financial Snapshot
Financial Snapshot inspireMD NYSE MKT: NSPR, NSPR.WS Average Volume: 190K Shares Outstanding (9/30/16): 14M Shares Outstanding Including Future Pref. Stock Conv. (9/30/16): cou Market Capitalization (10/14/16): $9.6 M $0.9 M as of 6/30/2016 Total Cash: ($13M net proceeds from financing completed on
Slide 24: Investment Highlights
Investment Highlights inspireMD + Revenue growth driven by broader EU and Latin American launch of CGuard * Strategic distribution partnership with Penumbra (NYSE: PEN) + Strong, and growing, direct sales teams across key countries * Significant growth in Italy over the last 4 quarters + Multiple an
Slide 25: InspireMD Contact
inspireMD James Barry, Ph.D., President and CEO Craig Shore, CFO 888.776.6804 888.776.6804 jimb@inspiremd.com craigs@inspiremd.com